These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12890852)

  • 1. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Kida Y
    N Engl J Med; 2003 Jul; 349(5):505-6; author reply 505-6. PubMed ID: 12890852
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Fukumoto S; Yamashita T
    N Engl J Med; 2003 Jul; 349(5):505-6; author reply 505-6. PubMed ID: 12892105
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
    N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What have we learnt about the regulation of phosphate metabolism?
    Blumsohn A
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):397-401. PubMed ID: 15199289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia.
    Fukumoto S; Yamashita T
    Endocr J; 2001 Dec; 48(6):603-10. PubMed ID: 11873859
    [No Abstract]   [Full Text] [Related]  

  • 6. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
    Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
    Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.
    Bowe AE; Finnegan R; Jan de Beur SM; Cho J; Levine MA; Kumar R; Schiavi SC
    Biochem Biophys Res Commun; 2001 Jun; 284(4):977-81. PubMed ID: 11409890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibroblast growth factor 23, a new phosphaturic factor in hypophosphatemic rickets/osteomalacia].
    Nishizawa Y; Imanishi Y
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():469-74. PubMed ID: 16279684
    [No Abstract]   [Full Text] [Related]  

  • 9. FGF23 and disorders of phosphate homeostasis.
    Yu X; White KE
    Cytokine Growth Factor Rev; 2005 Apr; 16(2):221-32. PubMed ID: 15863037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23, hypophosphatemia, and rickets: has phosphatonin been found?
    Strewler GJ
    Proc Natl Acad Sci U S A; 2001 May; 98(11):5945-6. PubMed ID: 11371627
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor-induced osteomalacia and the regulation of phosphate homeostasis.
    Kumar R
    Bone; 2000 Sep; 27(3):333-8. PubMed ID: 10962341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic osteomalacia--a complex dance of factors.
    Carpenter TO
    N Engl J Med; 2003 Apr; 348(17):1705-8. PubMed ID: 12711747
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolonged Hypophosphatemia and Intensive Care After Curative Surgery of Tumor Induced Osteomalacia: A Case Report.
    Ryhänen EM; Schalin-Jäntti C; Matikainen N
    Front Endocrinol (Lausanne); 2021; 12():686135. PubMed ID: 34149623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regulation of fibroblast growth factor 23 in metabolic bone diseases].
    Imanishi Y
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():486-91. PubMed ID: 16279687
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pathogenesis of hypophosphatemia].
    Takeuchi Y
    Clin Calcium; 2016 Feb; 26(2):199-205. PubMed ID: 26813499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic osteomalacia: is there a new phosphate regulating hormone?
    Nelson AE; Robinson BG; Mason RS
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):635-42. PubMed ID: 9497867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thoracic phosphaturic mesenchymal tumors causing oncogenic osteomalacia.
    Puthenveetil PJ; Hattab EM; Peacock M; Horn EM
    J Clin Neurosci; 2013 Aug; 20(8):1057-61. PubMed ID: 23618679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
    Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma.
    John MR; Wickert H; Zaar K; Jonsson KB; Grauer A; Ruppersberger P; Schmidt-Gayk H; Murer H; Ziegler R; Blind E
    Bone; 2001 Oct; 29(4):393-402. PubMed ID: 11595624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.